Does nivolumab combined with fluorouracil-based chemotherapy produce higher objective response rate than other immunochemotherapy regimes in metastatic esophageal cancer?: authors reply
Saved in:
Main Authors: | Zhen Gao (Author), Shujie Huang (Author), Sichao Wang (Author), Dezhao Tang (Author), Wei Xu (Author), Ruijie Zeng (Author), Guibin Qiao (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2023-10-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficacy and safety of immunochemotherapy, immunotherapy, chemotherapy, and targeted therapy as first-line treatment for advanced and metastatic esophageal cancer: a systematic review and network meta-analysisResearch in context
by: Zhen Gao, et al.
Published: (2023) -
Nivolumab for Metastatic Cutaneous Squamous Cell Carcinoma
by: Marcos Oro-Ayude, et al.
Published: (2020) -
Lenvatinib- and vadimezan-loaded synthetic high-density lipoprotein for combinational immunochemotherapy of metastatic triple-negative breast cancer
by: Chao Zheng, et al.
Published: (2022) -
A Novel Predictor of Pathologic Complete Response for Neoadjuvant Immunochemotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
by: Yang Y, et al.
Published: (2023) -
Enhanced IL-34 expression in Nivolumab-resistant metastatic melanoma
by: Nanumi Han, et al.
Published: (2018)